Glucose control and weight change associated with treatment with exenatide compared with basal insulin: A retrospective study
Diabetes Therapy Jan 12, 2018
Morgan CL, et al. - This retrospective study was designed to compare glycemic and weight change outcomes for type 2 diabetes patients treated with either exenatide once-weekly (EQW) or exenatide twice-daily (EBID) with those patients treated with basal insulin (BI). Compared with basal insulin, exenatide QW and exenatide BID were correlated with similar glycemic control and greater weight reduction.
Go to Original
Only Doctors with an M3 India account can read this article. Sign up for free or login with your existing account.
4 reasons why Doctors love M3 India
-
Exclusive Write-ups & Webinars by KOLs
-
Daily Quiz by specialty -
Paid Market Research Surveys -
Case discussions, News & Journals' summaries
